Keunok Jung, Miseon Kang, Cheol Park, Yung Hyun Choi, Youkyung Jeon, Se‐Ho Park, Su‐Kil Seo, Dan Jin, Inhak Choi – 18 June 2012 – V‐set and Ig domain‐containing 4 (VSIG4, CRIg, or Z39Ig), a newly identified B7‐related cosignaling molecule, is a complement receptor and a coinhibitory ligand that negatively regulates T‐cell immunity. Despite its exclusive expression on liver Kupffer cells (KCs) that play key roles in liver tolerance, the physiological role of VSIG4 in liver tolerance remains undefined.

Shao‐Lai Zhou, Zhi Dai, Zheng‐Jun Zhou, Xiao‐Ying Wang, Guo‐Huan Yang, Zheng Wang, Xiao‐Wu Huang, Jia Fan, Jian Zhou – 18 June 2012 – CXCL5 (epithelial neutrophil‐activating peptide‐78) is a member of a proangiogenic subgroup of the CXC‐type chemokine family of small, secreted proteins. Recently, evidence that CXCL5 is involved in carcinogenesis and cancer progression has emerged.

Kimihiko Murase, Yuichi Chihara, Kenichi Takahashi, Shinya Okamoto, Hajime Segawa, Kazuhiko Fukuda, Koichi Tanaka, Shinji Uemoto, Michiaki Mishima, Kazuo Chin – 12 June 2012 – Noninvasive ventilation (NIV) refers to ventilation delivered through a noninvasive interface (a nasal or face mask) rather than an invasive interface (an endotracheal tube or tracheostomy). The role of NIV in preventing reintubation after abdominal surgery in pediatric patients is uncertain. Therefore, we evaluated the role of NIV for this purpose in pediatric patients after liver transplantation.

Jyoti Srivastava, Ayesha Siddiq, Luni Emdad, Prasanna Kumar Santhekadur, Dong Chen, Rachel Gredler, Xue‐Ning Shen, Chadia L. Robertson, Catherine I. Dumur, Phillip B. Hylemon, Nitai D. Mukhopadhyay, Deepak Bhere, Khalid Shah, Rushdy Ahmad, Shah Giashuddin, Jillian Stafflinger, Mark A. Subler, Jolene J. Windle, Paul B. Fisher, Devanand Sarkar – 11 June 2012 – Astrocyte elevated gene‐1 (AEG‐1) is a key contributor to hepatocellular carcinoma (HCC) development and progression.

Morris Sherman, Jordi Bruix, Michael Porayko, Tram Tran, for the AASLD Practice Guidelines Committee – 11 June 2012

Olaf Neumann, Miriam Kesselmeier, Robert Geffers, Rossella Pellegrino, Bernhard Radlwimmer, Katrin Hoffmann, Volker Ehemann, Peter Schemmer, Peter Schirmacher, Justo Lorenzo Bermejo, Thomas Longerich – 11 June 2012 – To identify new tumor‐suppressor gene candidates relevant for human hepatocarcinogenesis, we performed genome‐wide methylation profiling and vertical integration with array‐based comparative genomic hybridization (aCGH), as well as expression data from a cohort of well‐characterized human hepatocellular carcinomas (HCCs).

Shunji Nagai, Lloyd Brown, Atsushi Yoshida, Dean Kim, Marwan Kazimi, Marwan S. Abouljoud – 9 June 2012 – Minimally invasive procedures are considered to be safe and effective approaches to the management of surgical liver disease. However, this indication remains controversial for living donor hepatectomy. Between 2000 and 2011, living donor right hepatectomy (LDRH) was performed 58 times. Standard right hepatectomy was performed in 30 patients via a subcostal incision with a midline extension. Minimally invasive procedures began to be used for LDRH in 2008.

Masahiro Takahashi, Seigo Nishida, Zubin J. Panthaki, Ji Fan, Antonio Romano, Akin Tekin, Eddie R. Island, Jang I. Moon, David M. Levi, Andreas G. Tzakis – 9 June 2012

Wenhua Liang, Linwei Wu, Xiaoting Ling, Paul M. Schroder, Weiqiang Ju, Dongping Wang, Yushu Shang, Yuan Kong, Zhiyong Guo, Xiaoshun He – 9 June 2012 – Because of the severe organ shortage, living donor liver transplantation (LDLT) offers a timely alternative to deceased donor liver transplantation (DDLT) for patients with hepatocellular carcinoma (HCC). However, the higher recurrence rate of HCC after LDLT and the indication criteria remain controversial.

Changhua Ji, Konduru S.R. Sastry, Georg Tiefenthaler, Jennifer Cano, Tenny Tang, Zi Zong Ho, Denise Teoh, Sandhya Bohini, Antony Chen, Surya Sankuratri, Paul A. Macary, Patrick Kennedy, Han Ma, Stefan Ries, Klaus Klumpp, Erhard Kopetzki, Antonio Bertoletti – 9 June 2012 – During antiviral therapy, specific delivery of interferon‐α (IFNα) to infected cells may increase its antiviral efficacy, trigger a localized immune reaction, and reduce the side effects caused by systemic administration.